Cargando…

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials

Although objective response rate and disease control rate are commonly used as primary endpoints of lung cancer trials, it remains unclear whether objective response rate and disease control rate correctly reflect the overall survival in a non-small cell lung cancer phase II trial evaluating a non-f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, Hiromi, Horita, Nobuyuki, Ito, Kentaro, Ebina-Shibuya, Risa, Hara, Yu, Kobayashi, Nobuaki, Kaneko, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182707/ https://www.ncbi.nlm.nih.gov/pubmed/34164275 http://dx.doi.org/10.21037/tlcr-20-1120

Ejemplares similares

Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials
por: Ebina-Shibuya, Risa, et al.
Publicado: (2021)

Inhaled Corticosteroid and Secondary Glaucoma: A Meta-analysis of 18 Studies
por: Ishii, Mai, et al.
Publicado: (2021)

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
por: Chen, Hao, et al.
Publicado: (2020)

Current national policies for infant universal bacille Calmette-Guérin vaccination were associated with lower mortality from coronavirus disease 2019
por: Ebina-Shibuya, Risa, et al.
Publicado: (2020)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis
por: Chen, Hao, et al.
Publicado: (2021)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

Clinical features of asthma with connective tissue diseases
por: Watanabe, Keisuke, et al.
Publicado: (2023)

The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Elderly sarcoidosis in Japan
por: Masumoto, Nami, et al.
Publicado: (2022)

Best regimens for treating chemo‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis
por: Horita, Nobuyuki, et al.
Publicado: (2017)

Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
por: Kobayashi, Nobuaki, et al.
Publicado: (2021)

Unusual lung involvements of invasive mucinous adenocarcinoma with chylothorax
por: Aoki, Ayako, et al.
Publicado: (2020)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy
por: Chen, Hao, et al.
Publicado: (2022)

The clinical significance of CXCL16 in the treatment of advanced non‐small cell lung cancer
por: Shibata, Yuji, et al.
Publicado: (2020)

Factors for Predicting Outcomes among Non-HIV Patients with Pulmonary Tuberculosis
por: Tsukahara, Toshinori, et al.
Publicado: (2017)

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study
por: Fujii, Hiroaki, et al.
Publicado: (2022)

HbA1c level cannot predict the treatment outcome of smear-positive non-multi-drug-resistant HIV-negative pulmonary tuberculosis inpatients
por: Tashiro, Ken, et al.
Publicado: (2017)

Clinical Features and Risk Factors for Mortality in Hospitalized Older Adults with Pneumonia
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer
por: Kamimaki, Chisato, et al.
Publicado: (2021)

Multisystem Inflammatory Syndrome in Children (MIS-C) with COVID-19: Insights from simultaneous familial Kawasaki Disease cases
por: Ebina-Shibuya, R., et al.
Publicado: (2020)

Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient
por: Matsumoto, Sachiko, et al.
Publicado: (2020)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
por: Kobayashi, Nobuaki, et al.
Publicado: (2020)

Assessment of diagnostic utility of serum hemeoxygenase-1 measurement for acute exacerbation of interstitial pneumonias
por: Kata, Yuki, et al.
Publicado: (2022)

Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses
por: Horita, Nobuyuki
Publicado: (2022)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Genetic model selection for a case–control study and a meta-analysis
por: Horita, Nobuyuki, et al.
Publicado: (2015)

An Early Screening Tool for Discharge Planning Shortened Length of Hospital Stay for Elderly Patients with Community-Acquired Pneumonia
por: Chen, Hao, et al.
Publicado: (2021)

Reply to letter to the editor “antibody responses to second doses of COVID-19 vaccination in lung cancer patients: Comment”
por: Narita, Daisuke, et al.
Publicado: (2023)

The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study
por: Aoki, Ayako, et al.
Publicado: (2023)

Age, Dehydration, Respiratory Failure, Orientation Disturbance, and Blood Pressure Score Predicts In-hospital Mortality in HIV-negative Non-multidrug-resistant Smear-positive Pulmonary Tuberculosis in Japan
por: Nagai, Kenjiro, et al.
Publicado: (2016)

Role of thymic stromal lymphopoietin in allergy and beyond
por: Ebina-Shibuya, Risa, et al.
Publicado: (2022)

TSLP‐targeting therapy: Beyond allergy?
por: Ebina‐Shibuya, Risa, et al.
Publicado: (2023)

Declined Functional Status Prolonged Hospital Stay for Community-Acquired Pneumonia in Seniors
por: Chen, Hao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vvlf0t46n9a4beo7j737li8afk